As novel therapies like blinatumomab and ponatinib achieve excellent systemic control of B-ALL, central nervous system (CNS) relapse emerges as a primary hurdle. This was noted in this trial and others, highlighting a critical unmet need to develop effective, non-chemotherapeutic strategies for CNS prophylaxis and treatment.

With new CNS-active drugs dramatically improving survival after a brain metastasis diagnosis, some experts are now advocating for routine screening brain MRIs in high-risk patients. The goal is to detect asymptomatic lesions early, potentially preventing catastrophic neurologic events like seizures.

Modern therapies have dramatically improved survival for high-risk CLL patients. However, this group paradoxically represents the largest unmet need, as they are the most likely to develop resistance to the main drug classes over decades, driving research into novel mechanisms like degraders and non-covalent inhibitors.

For patients with otherwise well-controlled disease who develop isolated oligoprogression in the brain, evidence suggests a better survival outcome from adding local therapy (like SRS) and continuing the current effective systemic therapy, rather than switching the systemic regimen entirely.

Experts anticipate trials that use ctDNA to detect minimal residual disease (MRD) after standard frontline DLBCL therapy. Patients who remain MRD-positive could then be escalated to consolidation therapy with CAR T-cells, potentially improving long-term outcomes for high-risk individuals.

When treating testicular DLBCL, administering systemic methotrexate for CNS prophylaxis before testicular radiation is crucial. Reversing the order can cause a severe skin reaction known as radiation recall, a critical and potentially dangerous complication.

While blinatumomab-TKI combinations avoid systemic chemotherapy toxicity, they are associated with higher rates of central nervous system (CNS) relapses. This necessitates an increased number of intrathecal chemotherapy doses to prevent CNS disease, a critical nuance for managing this 'simpler' approach.

The interpretation of ctDNA is context-dependent. Unlike in the adjuvant setting, in the neoadjuvant setting, remaining ctDNA positive post-treatment signifies that the current therapy has failed. These high-risk patients need a different therapeutic approach, not an extension of the ineffective one.

Administering IT chemotherapy during a lumbar puncture is an outdated practice for CNS prophylaxis in DLBCL. Its penetration into the brain parenchyma is minimal (~3mm), rendering it useless against parenchymal recurrences, the most common type of CNS relapse. The focus should be on systemic agents with better CNS penetration.